Objective To investigate the clinical efficacy of drug-coated balloons in percutaneous coronary intervention (PCI) for patients with unstable angina pectoris caused by coronary heart disease. Methods Ninety-seven patients with unstable angina pectoris caused by coronary heart disease who underwent percutaneous coronary intervention in Xuzhou Renci Hospital from August 2019 to June 2022 were selected and divided into a control group (48 cases) and an observation group (49 cases) according to the treatment methods. There were 25 males and 23 females in the control group; they were (61.58±4.15) years old. There were 26 males and 23 females in the observation group; they were (61.65±4.22) years old. The control group took stent implantation treatment, and the observation group drug-coated balloon dilation treatment. Both groups were followed up for 12 months. The cardiac function, reference vessel diameters (RVD), minimum lumen diameters (MLD), late stage luminal loss, quality of life, and overall incidences of adverse cardiovascular events were compared between the two groups. t and χ2 tests were applied.Results Before the surgery, the ejection fraction (EF), cardiac output (CO), and cardiac index (CI) in control group were (75.24±7.31) %, (2.63±0.60) L/min and (4.08±0.71) L/ (min•m2), and those in the observation group (74.85±7.26) %, (2.57±0.61) L/min, and (3.37±0.71) L/(min•m2); after the surgery, the EF, CO, and CI in the control group were (86.03±10.17) %, (4.61±0.79) L/min and (4.08±0.71) L/(min•m2), and those in the observation group (86.64±10.23) %, (4.52±0.76) L/min, and (4.15±0.67) L/(min•m2); there were no statistical differences in the cardiac function between the two groups before the surgery (all P>0.05); the EF, CO, and CI increased after the surgery in both groups, with statistical differences between before and after the surgery in both groups (all P<0.05), but no between the two groups after the surgery (all P>0.05). Immediately after surgery, the RVD and MLD in the control group were (2.57±0.29) mm and (0.57±0.14) mm, and those in the observation group were (2.53±0.26) mm and (0.59±0.12) mm, respectively. Twelve months after the surgery, the RVD and MLD in the control group were (2.68±1.09) mm and (2.03±0.33) mm, and those in the observation group were (2.73±1.12) mm and (1.98±0.34) mm, respectively; immediately and 12 months after the surgery, there were no statistical differences in RVD and MLD between the two groups (all P>0.05); twelve months after the surgery, the MLD increased in both groups (both P<0.05), but there were no statistical differences in RVD and MLD between the two groups. Twelve months after the surgery, the late stage luminal loss in the observation group was (0.32±0.20) mm, while that in the control group was (0.36±0.22) mm, with no statistical difference (t=-0.937, P=0.351). There was no statistical difference in the quality of life score between the two groups before the surgery (P>0.05). Twelve months after the surgery, the scores of physiological function, physical pain, physiological function, vitality, social function, overall health, emotional function, and mental health increased in both groups, and the scores of physiological function, overall health, and mental health in the observation group were higher than those in the control group (all P<0.05). Twelve months after the surgery, there was no statistical difference in the total incidence of adverse cardiovascular events between the two groups [12.24% (6/49) vs. 8.33% (4/48); P>0.05]. Conclusion The application of drug-coated balloons in the treatment of patients with unstable angina pectoris caused by coronary heart disease is equivalent to the stent implantation in effectiveness and safety, but the patients' quality of life after drug-coated balloon treatment is higher.